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Total Elbow Arthroplasty: A Prospective Clinical Outcome Study of Discovery Elbow 1 
System with a 4-Year Mean Follow-Up 2 
Abstract 3 
Background: Total elbow arthroplasty (TEA) is increasingly used for the treatment of 4 
advanced elbow conditions to reduce pain and improve function. However, TEA is still 5 
associated with a higher complication rate compared to the total hip and knee arthroplasty 6 
despite advances in the design and surgical techniques. This prospective clinical study reports 7 
the outcome of the Discovery Elbow System (Biomet Inc., Warsaw IN, USA) system which 8 
has been in clinical use in the UK since 2003.  9 
 10 
Methods: The study included a total of 100 Discovery elbows (April 2003 to January 2010) 11 
with a minimum 2-year follow-up including 75 primary and 25 revisions (60 % females and 12 
40% males; mean age, 62 years). Outcome was assessed by means of Liverpool Elbow Score, 13 
pain experience, patient satisfaction, range of movement, and radiographic imaging.  14 
 15 
Results: Mean follow-up was 48.5 months (range: 24-108 months). Liverpool Elbow Score   16 
improved from 3.79 to 6.36 (P<.001). Pain-free patients were substantially increased form 17 
7% preoperatively to 64% at the final follow-up. Patient satisfaction rate was over 90%. The 18 
arc of flexion-extension and pronation-supination increased from 72º to 93º and from 86º to 19 
111º, respectively (P<.001). Major post-operative complications included deep infection 20 
(2%), progressive aseptic loosening requiring revision (primary, 5%; revision 12%), 21 
persistent ulnar neuropathy (3%), and periprosthetic fracture (primary, 6.8%; revision, 8%).  22 
 23 
Conclusion: Discovery elbow resulted in improved function, reduced pain, and high patient 24 
satisfaction. Long-term results are required for assessing the survivorship of this system.  25 
 26 
Keywords: Total Elbow Arthroplasty; Discovery Elbow; Clinical Outcome; Elbow 27 
Prostheses.  28 
Level of Evidence: Level III 29 
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BACKGROUND 30 
Total elbow arthroplasty (TEA) has increasingly become a popular reconstructive procedure 31 
due to improved surgical techniques, advanced implant designs, and enhanced clinical 32 
outcomes.39 The modern era of TEA began in the late 1970s when the prosthetic design 33 
evolved following several key developments: the use of high-density polyethylene as a 34 
bearing surface to metal, the use of methyl methacrylate bone cement, and the 35 
implementation of biomechanical science to reproduce normal joint kinematics.7 Modern 36 
TEA implants are designed as linked or unlinked. Linked implants are coupled together 37 
through a hinge allowing for some degrees of laxity in the medial, lateral, and rotational 38 
planes consistent with normal elbow kinematics. A “sloppy hinge,” design is associated with 39 
a reduced the rate of aseptic loosening and instability of the articulation.32 Unlinked implants 40 
are not mechanically coupled and mostly rely on matching shapes of the bearing surfaces, 41 
adequate bone stock, and, the integrity of capsular and ligamentous structures.5,7 Unlinked 42 
designs have been associated with higher rate of instability as their stability mainly depends 43 
on their geometry and surrounding soft tissues (ligaments and bone stock) rather than the 44 
intrinsic constraint of the articulation.5 45 
 46 
The use of unlinked prostheses may be preferred when there is less bone or articular 47 
destruction and in younger patients who may need later revision surgery. From the other 48 
hand, the increased stability of the linked implants has expanded their use in conditions with 49 
increased bone destruction and ligamentous incompetency such as advanced stages of 50 
rheumatoid arthritis, posttraumatic and degenerative osteoarthritis, and complex distal 51 
humerus and intra-articular fractures (particularly in elderly patients).5,7,21 52 
 53 
Despite considerable developments in the prosthetic design, TEA has been associated with a 54 
high rate of complications, ranging from 20% to 45%, compared to other main total joint (hip 55 
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and knee) replacements14,25,37 potentially because of the difficulty of surgical procedure in a 56 
complex joint with minimal soft tissue support.10 Gschwend et al,14 reviewed the literature 57 
and reported an overall complication rate of up to 43% including aseptic loosening, 58 
infections, ulnar nerve complications, instability, disassembly, dislocation, subluxation, 59 
intraoperative fractures, fractures of the prosthesis, implant loosening, periprosthetic fracture, 60 
triceps insufficiency, and ectopic bone formation. In another review, Little et al,25 reported a 61 
complication rate of 14%-80% including deep infection and septic loosening (up to 10%), 62 
ulnar neuropathy with permanent dysfunction (up to 10%), hinge failure (up to 6%), and 63 
polyethylene bushing wear (14% to 47%) for various semiconstrained prostheses. 64 
 65 
The Discovery Elbow System (Biomet Inc, Warsaw, IN, USA), was developed with the 66 
intention of addressing some of above issues associated with previous linked designs by 67 
means of decreasing polyethylene bushing wear, reinforcing anatomic stem design, restoring 68 
natural elbow joint biomechanics, and producing a hinge that could be easily revised.16 The 69 
Discovery elbow has been in clinical use in the UK since 2003. The structural specifications 70 
and design rationale of the system have been described in full details by Hastings and 71 
Theng18 and Hastings.16  72 
 73 
This study aimed to 1) report functional and radiological outcome of the Discovery elbow in 74 
a large series of primary and revision TEAs with various elbow pathologies; and 2) compare 75 
the clinical outcome and complications with published literature on other prostheses.  76 
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PATIENTS AND METHODS 77 
One hundred Discovery elbows with a minimum 2-year follow-up were included in the study. 78 
All TEAs were performed in a single centre by the same surgeon (April 2003 to January 79 
2010). The technical properties of the prosthetic system and surgical technique have been 80 
described in full details by Hastings et al.16  81 
The mean age of patients (females, 60 %; males, 40%) was 62 years (range: 22-86), weight 82 
71.8kg (±18.3), and height 166 (±12.5). The mean follow-up period was 48.5 months (range: 83 
24-108 months). Inclusion criteria were advanced arthritis unresponsive to non-operative 84 
management, acute distal humerus fracture and revision for loosening of other elbow 85 
prostheses in skeletally mature patients (>18 years old). Exclusion criteria included 86 
systematic metabolic diseases affecting the bone formation and active infection. The main 87 
underlying pathologies (diagnoses) are outlined in Table1. Primary and revision TEA 88 
comprised 75% and 25% of the cases, respectively. Study received approval from a local 89 
research ethics committee and all patients gave informed consent prior to the surgery.  90 
 91 
FOLLOW UP ASSESSMENT 92 
Functional Outcome 93 
Main clinical information and data including underlying pathology (primary diagnosis), type 94 
of TEA (primary, revision), follow-up period, pain experience, patient satisfaction, range of 95 
movement (flexion/extension of the elbow and pronation/supination of the forearm), and 96 
complications were collected using a purpose-designed elbow arthroplasty proforma. A 97 
validated elbow score, Liverpool Elbow Score (LES), was also used for functional 98 
assessment.33,38 The patient-rated section of the LES has good correlation to MEPS and has 99 
been suggested as an outcome measure for evaluating results of TEA.4 The AO handbook for 100 
Musculoskeletal Outcomes Measures and Instruments rated this score as a superior quality 101 
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outcome assessment tool compared to the Mayo Elbow Performance Score (MEPS).36 A 102 
score of 0 and 10 indicate worst and best outcome, respectively. 103 
 104 
Radiographic assessment  105 
Where available, the anterioposterior and lateral views of pre- and postoperative plain x-rays 106 
(Figure.1) were reviewed for humeral and ulnar stem alignment in sagittal and coronal 107 
planes, aseptic loosening, periprosthetic fracture, dislocation, and hypertropic ossification. 108 
Imaging assessment pattern followed the principles explained in a recent comprehensive 109 
radiographic review of TEA.29 For assessing the component alignment, angles between the 110 
axis of the shaft of humerus and the stem of the humeral component and between the axis of 111 
the shaft of ulna bone and the stem of the ulnar component were measured in the early post- 112 
operative x-rays.12 A malalignment of >10º was considered as significant.11,12,37 113 
Periprosthetic fracture was evaluated based on Mayo Classification System (Figure.2).28 114 
  115 
Data Analysis 116 
Continuous and descriptive data are reported as mean and standard deviation (Mean + SD) 117 
and 95% confidence interval. Categorical data are described using proportion and percentage. 118 
Paired Student t test or ANOVA were used to compare the preoperative LES and ROM with 119 
those at the final follow-up for the entire patient group and according to underlying pathology 120 
(primary diagnosis) and type of TER (primary, revision), as appropriate. The level of 121 
significance was set at 5 % (p < 0.05). SPSS package (IBM SPSS Statistics for Windows, 122 
Version 21.0. Armonk, NY: IBM Corp.) was used for data analysis.  123 
Clinical Outcome of the Discovery Elbow 
 
6 
 
RESULTS 124 
Functional Outcome Results 125 
Preoperatively, 61% and 21% of patients experienced severe and moderate pain, respectively 126 
which was then reduced to 11% and 14% post-operatively. The percentage of pain-free 127 
patients was substantially increased form 7% preoperatively to 64% at the final post-128 
operative follow-up. In terms of patient satisfaction, 63%, 8%, and 23% of patients were 129 
classified as ‘Very Satisfied’, ‘Somewhat Satisfied’, and ‘Satisfied’, respectively. Only 6% 130 
remained unsatisfied with the outcome mainly involving revision cases. 131 
 132 
The mean preoperative and final follow-up LES were 3.79 (±1.71) and 6.36 (±1.85), 133 
respectively which highlighted a significant improvement (p< 0.001). Similar improvements 134 
were observed for all main pathology groups (inflammatory and non-inflammatory arthritis, 135 
and Fracture), however, LES improvement was significantly higher in the primary (6.41±17) 136 
compared to revision TEA (5.78±14) (p<0.05). Table 2 summarises the results of ROM for 137 
flexion and extension of the elbow and pronation and supination of the forearm for entire 138 
patient group and according to the main diagnoses. Except elbow extension (extension lag) 139 
all movements including flexion-extension and pronation-supination arc were significantly 140 
improved. ROM improvements in revision TEA were comparable with those of primary 141 
TEA. 142 
Radiographic Assessment Results 143 
Imaging was available for 88 TEAs (88%) (primary, 70; revision, 18). Table3 presents the 144 
degree of alignment of humeral and ulnar components (stems) in both sagittal and coronal 145 
planes. Around 90% of the evaluated TEAs presented with a good alignment (<5º) for both 146 
components in both planes. A significant malalignment (>10º) was seen in one primary TEA 147 
elbow; however it was not associated with early loosening.  148 
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The overall incidence of periprosthetic fracture was 14.8% (primary, 6.8%; revision, 8%) 149 
involving humeral condyles and olecranon in 9.1% and 5.7% of elbows, respectively. All 150 
fractures were classified as Mayo Type 1 and managed conservatively. Hypertropic 151 
ossification occurred in 6.8% of TEAs (primary, 5.7%; revision, 1.1%).  152 
In the primary group, areas of non-progressive lucency were noted around the bone-cement 153 
interface of 10 TEAs without any further progression. Marked osteolysis around the humeral 154 
component observed in two cases but the prosthesis remained stable with no need for 155 
revision. Four TEAs developed significant osteolysis and required revision of either humeral 156 
component (n=3) or both humeral and ulnar components (n=1). In the revision group, non-157 
progressive lucency was noted in seven TEAs. Marked osteolysis occurred in one elbow 158 
(humeral component); however, prosthesis remained stable with no need for revision. Three 159 
revision cases developed progressive loosening of both humeral and ulnar components; two 160 
underwent 2nd revision and one is awaiting revision. 161 
Complications 162 
In addition to the complications reported in the radiographic assessment results 163 
(malalignment, periprosthetic fracture, aseptic loosening, and hypertrophic ossification), deep 164 
infection occurred in 2 cases (both required a 2-stage revision), persistent ulnar neuropathy in 165 
3 cases (managed with nerve decompression and transposition), and prosthetic failure 166 
(dissociation of the condyle and screws from main components) in 1 case (revised).   167 
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DISCUSSION 168 
Despite recent developments in the design of elbow prostheses, advances in surgical 169 
techniques, and marked improvements in pain and function, TEA is still associated with high 170 
complication and revision rates compared to hip and knee arthroplasty.7,38,40 This high 171 
complication rate is partly related to the anatomical characteristics of the elbow such as 172 
insufficient bone stock for implantation and lack of strong supporting soft tissue.3,23  173 
 174 
Elbow prostheses have been used for decades in linked (e.g. Coonrad-Morrey, GSB III, 175 
Triaxial, Discovery System) and unlinked (e.g. Kudo, Souter-Strathclyde, IBP) or both linked 176 
and unlinked (e.g. Acclaim) modes. The Discovery elbow is a linked prosthesis with a design 177 
that mimics the anatomical characteristics and kinematics of the elbow joint. The present 178 
study reports the clinical outcome of TEA with this system over a 4-year mean follow-up and 179 
compares the results with other reports. However, direct comparison of clinical outcomes 180 
amongst different TEA implants is a challenging task because of heterogeneity in reporting 181 
methods of function, pain experience, patient satisfaction, and radiographic assessment.  182 
 183 
Pain relief is one of the prime benefits following any joint arthroplasty. In the present study, 184 
around 64% of cases had no pain at the final follow-up. The majority of the studies on TEA 185 
have used percentage of patients with no pain or mild pain as measure of success of the 186 
procedure. By that standard, 78% of our cases had either no pain or only mild pain at final 187 
follow-up. The percentage of patients with no pain or mild pain after undergoing Acclaim,6 188 
Souter-Strathclyde,31 GSB III14,22,34 and Coonrad-Morrey25,35 have been reported as 64%, 189 
67%, 50–92% and 60-100%, respectively. Overall the patient satisfaction rate for our series 190 
was 94% with 63% of patients reporting maximal satisfaction (Very Satisfied). A study of 191 
different linked prostheses (11 elbows) reported a 73% satisfaction rate.40 In a study of 51 192 
elbows using the Coonrad-Morrey prosthesis, Hildebrand et al,19 reported patient satisfaction 193 
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of 9.2/10 in inflammatory arthritis and 8.6/10 in posttraumatic arthritis. A recent study of 194 
Discovery Elbow replacement patients in 46 elbows reported a patient satisfaction rate of 195 
9.1/10.17 196 
 197 
Functional capacity was markedly improved in our cohort of patients according to the LES 198 
which integrates both patient self-evaluation and clinician’s assessments. The majority of 199 
TEA studies, however; chose to use MEPS for functional assessment. Considering the strong 200 
correlation between LES and MEPS,4 the marked improvement found for the LES in the 201 
present study are in line with those reported for other prostheses.2,24-26,30 The mean 202 
improvement in flexion-extension arc in our TEA series was 21º. Based on systematic 203 
reviews of semiconstrained linked and unlinked TEA prostheses, the average improvement in 204 
flexion-extension arc ranged between 12º-39º with a weighted improvement of 26°.25,38 205 
According to individual studies, the mean improvement in flexion-extension arc with 206 
Acclaim,6 Souter-Strathclyde,31 GSB III,20,22 and Coonrad-Morrey prostheses35 were 23º, 15º, 207 
19º-33º and 17º-26º, respectively. A recent study of 46 Discovery elbows reported an 208 
improvement of 40º in flexion-extension arc.17 The mean improvement in pronation-209 
supination arc in our series was 25º. This movement arc has been reported as 21º-28º for 210 
Coonrad-Morrey prosthesis35 and 31º-67º for GSB III prosthesis.20,22 Hastings et al,17 211 
reported an increase of 29º in pronation-supination arc with Discovery elbow. It has to be 212 
taken into consideration that our reported results combine both primary and revision TEAs.  213 
 214 
Deep infection remains the most worrying complication with a rate of around 4% infection 215 
reported in longer-term TEA studies.9,25 The overall incidence of deep infection in our series 216 
was 2%. The incidence of deep infection with GSB III TEA has varied between 4%-217 
11%.14,22,34 Studies on Coonrad-Morrey TEA have reported an infection incidence rate of 218 
6%-8%.19,25 Hastings et al,17 recently summarised complications for Coonrad-Morrey, GSB 219 
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III, Solar, and Discovery prostheses in 595 TEA patients (561 primary, 34 revision) and cited 220 
the average rate of deep infection as 2.9%. 221 
 222 
Progressive aseptic loosening requiring revision occurred in 4 primary (5%) and 3 revision 223 
(12%) of our series. This complication has been reported in association with other linked 224 
prostheses including Coonrad-Morrey (0%-7%),1,13,15,19,25 GSB III (4%-29%),8,14,20,34 and 225 
Souter-Strathclyde (up to 31%).15,24,30 Summarising the complication reports from linked 226 
devices, Hastings et al,17 and Kelly et al,22 have cited the average rate of primary aseptic 227 
loosening as 8.9% and 4%-50%, respectively. In a recently published study of 46 Discovery 228 
elbow cases, the rate of aseptic loosening was 2.2%.17   229 
 230 
The overall rate of periprosthetic fracture and cortical perforation was 14.8% (primary, 6.8%; 231 
revision, 8%) in the present study. All fractures were classified as Mayo Type 1 and required 232 
conservative management. The incidence of periprosthetic fractures with Acclaim,6 GSB 233 
III,20,34 and Coonrad-Morrey19 has been reported as 36%, 16%-21%, and 23%, respectively.  234 
 235 
Incidence of persistent ulnar neuropathy requiring surgical intervention was 3% in our series. 236 
Ulnar neuropathy is seen more commonly in rheumatoid arthritis as close proximity of the 237 
nerve to the elbow joint can lead to inflammation of the nerve due to synovitis in the nearby 238 
elbow joint and valgus instability can lead to stretching of the ulnar nerve.27 The incidence 239 
rate of ulnar neuropathy with GSB III, Coonrad-Morrey, and Acclaim has been reported as 240 
11%-14%,8,22 12%-26%,1,19 and 8%,6 respectively. Summarising the complications of TEA in 241 
595 patients, Hastings et al,17 cited a rate of 4.4% for ulnar neuropathy.  242 
 243 
The present study provided comprehensive prospective clinical outcome data on for the 244 
Discovery elbow arthroplasty. The study included a large cohort of primary and revision 245 
TEAs which reduced the scope of selection bias. Furthermore, clinical and radiographic 246 
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assessments were performed by independent assessors other than the principal surgeon 247 
thereby decreasing the possibility of information bias. There were, however, some limitations 248 
to the study. First, study included both primary and revision TEAs which might have some 249 
effect on reported outcome results. In order to address this, significant differences between 250 
primary and revision TEAs in outcome measures (e.g. LES) and complications rates are 251 
highlighted in the paper. Second, study used LES as a key functional assessment tool. This 252 
reduced the scope of comparisons with other studies into some extent as based around half of 253 
recent outcome reports used MEPS.25 Hence, MEPS was added into our functional 254 
assessment tools a few years ago and being completed in addition to LES for all prospective 255 
TEAs. Third, a 4-year mean follow-up provides a relatively reasonable period for functional 256 
outcome report but a longer term follow-up is required for assessing late complications and 257 
survivorship of the prosthesis.    258 
Clinical Outcome of the Discovery Elbow 
 
12 
 
CONCLUSION 259 
The results indicate that Discovery elbow is a system viable option for the treatment of 260 
advanced inflammatory and non-inflammatory elbow conditions where a TEA is indicated. 261 
This was reflected in significant improvements in LES, range of movement, pain experience, 262 
and a high patient satisfaction score at a 4-year mean follow-up. The incidence of 263 
complications was either comparable or less than that reported for other linked prostheses. 264 
We need to wait for the long term results of this prosthesis to assess its survivorship.  265 
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Figure and Table Legends 375 
Figure1. Lateral and anteroposterior x-rays of an elbow with osteoarthritis before (a-b) and 376 
6-year after total elbow arthroplasty with Discovery Elbow (c-d). 377 
Figure2. Graphic illustration of the Mayo Clinic classification system used for describing 378 
periprosthetic fractures in elbow arthroplasty. It is important to differentiate between different 379 
types of fractures as those affecting the hardware stems (types 2 and 3) will potentially 380 
require revision. (Reprinted with permission from RadioGraphics.29  381 
Table1. Incidence of diagnoses for primary and revision Total Elbow Arthroplasty (TEA) 382 
Table2. Comparison of pre- and postoperative elbow and forearm range of motion with 383 
Discovery Elbow according to main underlying pathologies in all patients (primary and 384 
revision) 385 
Table3. Prosthesis alignment in primary and revision Total Elbow Arthroplasty (TEA) 386 
 Table1. Incidence of diagnoses for primary and revision Total Elbow Arthroplasty (TEA)  
 
Main Diagnoses and sub-diagnoses 
Incidence (%) 
(n = 100 elbows) 
Inflammatory Arthritis  
          Rheumatoid Arthritis 54 
          Juvenile Rheumatoid Arthritis 2 
         Psoriatic Arthritis 2 
 
Non-Inflammatory Arthritis  
          Degenerative Osteoarthritis 17 
          Traumatic Arthritis 14 
          Haemophilic Arthropathy 3 
         Nail–patella syndrome    1 
 
Distal Humerus Fracture (acute and non-union) 7 
Total TEA 100 
 
 
Revision TEA  
          Inflammatory Arthritis 16 
         Non-Inflammatory Arthritis 7 
         Fracture 2 
 
Total 25 
 
 
Table2. Comparison of pre- and postoperative elbow and forearm range of motion with 
Discovery Elbow according to main underlying pathologies in all patients (primary and revision) 
 
Elbow/Forearm 
ROM 
All Patients  Non-Inflammatory 
(Osteoarthritis) 
Inflammatory 
(Rheumatoid Arthritis) 
Fracture 
Pre-op Post-op Pre-op Post-op Pre-op Post-op Pre-op Post-op 
Flexion 100 (24) 118 (17)** 101 (26) 118 (18) * 100 (20) 117 (16)** 92 (38) 115 (28) 
Extension lag 28 (14) 25 (14) 28 (11) 25 (12) 28 (16) 26 (16) 23 (15) 18 (17) 
FLX-EXT ARC 72 (28) 93 (27)** 73 (30) 93 (26)* 72 (27) 92 (26)** 87 (33) 97 (44) 
Pronation 48 (23) 61 (21)** 49 (25) 64 (18)* 46 (23) 59 (22)* 61 (17) 64 (15) 
Supination 38 (26) 50 (25)** 42 (26) 55 (21)* 35 (26) 45 (25)* 52 (23) 51 (29) 
PRON-SUP ARC 86 (45) 111 (42)** 91 (48) 119 (35)** 81 (44) 104 (42)* 113 (39) 115 (41) 
-FLX, Flexion; EXT, Extension; ROM, Range of Motion; Pre-op, Preoperative; Post-op, Postoperative.  
-Significant difference at P < .05 (*) and P < .001 (**). 
 
Table3. Prosthesis alignment in primary and revision Total Elbow Arthroplasty (TEA) 
Degree of Malalignment 
Coronal Plane Sagittal Plane 
Humerus Ulna Humerus Ulna 
 
PRIMARY TEA 
Less than 5 degrees  61 57 48 63 
5-10 degrees  9 13 22 6 
More than 10 degrees  0 0 0 1 
 
REVISION TEA 
Less than 5 degrees  16 16 14 17 
5-10 degrees  2 2 4 1 
More than 10 degrees  0 0 0 0 
 
 


